Form 4: West Pharmaceutical Services Officer Reports Stock Transactions

Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services, reports the acquisition and disposal of common stock and stock options.

Summary

• Chad Winters, VP, Chief Accounting Officer of West Pharmaceutical Services, filed a Form 4 on February 20, 2025.
• The report details transactions that occurred on February 18, 2025.
• Winters acquired 82.054 shares of common stock through the exercise of stock options at a price of $211.
• He also disposed of 27.727 shares of common stock to cover tax obligations at a price of $211.
• Following these transactions, Winters directly owns 1,363.025 shares of common stock.
• Winters was also granted 822 stock options exercisable beginning February 18, 2026, and expiring February 18, 2035.
• He was also granted 356 restricted stock units that vest in four equal installments beginning on February 18, 2026.
• A Limited Power of Attorney was executed on May 15, 2024, granting Luis Cantarero, Louis Lalli, Ryan Metz, and Caitlin Hippeli the authority to file Section 16(a) forms on behalf of Chad Winters.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.

Positives

• The acquisition of shares through option exercise indicates a belief in the company's future prospects.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces Winters' direct holdings.

Risks

• There are no specific risks highlighted in this document, as it primarily reports stock transactions.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into insider transactions. This filing indicates the actions of a key officer at West Pharmaceutical Services.

Comparison to Industry Standards

• Insider transactions are common across publicly listed companies.
• The details provided in the Form 4 are standard for compliance with SEC regulations.
• Similar filings can be observed for officers and directors at comparable companies in the pharmaceutical and healthcare sectors, such as Johnson & Johnson, Pfizer, and Merck.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders by providing insight into management's perspective on the company's stock.

Key Dates

Keywords

Form 4, stock options, common stock, insider trading, West Pharmaceutical Services, Winters, Section 16(a)